The cancer-immunity cycle: Indication, genotype, and immunotype

I Mellman, DS Chen, T Powles, SJ Turley - Immunity, 2023 - cell.com
The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Activated fibroblasts in cancer: Perspectives and challenges

G Caligiuri, DA Tuveson - Cancer cell, 2023 - cell.com
Activated fibroblasts in tumors, or cancer-associated fibroblasts (CAFs), have become a
popular research area over the past decade. As important players in many aspects of tumor …

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

WL Hwang, KA Jagadeesh, JA Guo, HI Hoffman… - Nature …, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Clinical and therapeutic relevance of cancer-associated fibroblasts

Y Chen, KM McAndrews, R Kalluri - Nature reviews Clinical oncology, 2021 - nature.com
Cancer-associated fibroblasts (CAFs) found in primary and metastatic tumours are highly
versatile, plastic and resilient cells that are actively involved in cancer progression through …

[HTML][HTML] Fibroblasts in cancer: Unity in heterogeneity

Y Chhabra, AT Weeraratna - Cell, 2023 - cell.com
Tumor cells do not exist in isolation in vivo, and carcinogenesis depends on the surrounding
tumor microenvironment (TME), composed of a myriad of cell types and biophysical and …

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Intratumoral heterogeneity in cancer progression and response to immunotherapy

I Vitale, E Shema, S Loi, L Galluzzi - Nature medicine, 2021 - nature.com
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

[HTML][HTML] Spatially confined sub-tumor microenvironments in pancreatic cancer

BT Grünwald, A Devisme, G Andrieux, F Vyas, K Aliar… - Cell, 2021 - cell.com
Intratumoral heterogeneity is a critical frontier in understanding how the tumor
microenvironment (TME) propels malignant progression. Here, we deconvolute the human …

Concepts of extracellular matrix remodelling in tumour progression and metastasis

J Winkler, A Abisoye-Ogunniyan, KJ Metcalf… - Nature …, 2020 - nature.com
Tissues are dynamically shaped by bidirectional communication between resident cells and
the extracellular matrix (ECM) through cell-matrix interactions and ECM remodelling …

Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data

AA Connor, S Gallinger - Nature Reviews Cancer, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …